• Publications
  • Influence
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
  • J. Sosman, Kevin B Kim, +22 authors A. Ribas
  • Medicine
  • The New England journal of medicine
  • 23 February 2012
Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma, and the median overall survival in this study with a long follow-up was approximately 16 months. Expand
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays
It is demonstrated that Merkel cell polyomavirus is a widespread but previously unrecognized human infection and MCC patients have a markedly elevated MCV IgG response compared with control patients. Expand
Genomic Classification of Cutaneous Melanoma
This clinicopathological and multi-dimensional analysis suggests that the prognosis of melanoma patients with regional metastases is influenced by tumor stroma immunobiology, offering insights to further personalize therapeutic decision-making. Expand
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
BACKGROUND Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety ofExpand
Leptin in Immunology1
Recent advances on the role of leptin in the pathophysiology of immune responses are reviewed and it is confirmed that leptin promotes Th1 cell differentiation and cytokine production. Expand
Leptin and reproduction: a review.
Leptin may act as the critical link between adipose tissue and the reproductive system, indicating whether adequate energy reserves are present for normal reproductive function and providing new therapeutic options for the reproductive dysfunction associated with states of relative leptin deficiency or resistance. Expand
Next generation of immunotherapy for melanoma.
The successes of cytokine and interferon therapy of melan cancer, coupled with an array of new approaches, are generating new enthusiasm for the immunotherapy of melanoma. Expand
Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity.
Treatment with a melanocortin agonist is a promising therapeutic approach to DIO and associated insulin resistance as well as peripheral MTII improves insulin resistance in DIO mice. Expand
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Vemurafenib inhibits tumor proliferation and oncogenic BRAF signaling through the MAPK pathway and inhibition downstream of BRAF should help to overcome acquired resistance. Expand
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
It is demonstrated that MERTK expression correlates with disease progression and is established as a therapeutic target in melanoma and provides a rationale for the continued development of MertK-targeted therapies. Expand